GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Granules India Ltd (NSE:GRANULES) » Definitions » Debt-to-EBITDA

Granules India (NSE:GRANULES) Debt-to-EBITDA : 1.28 (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Granules India Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Granules India's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹11,629 Mil. Granules India's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹1,522 Mil. Granules India's annualized EBITDA for the quarter that ended in Mar. 2024 was ₹10,303 Mil. Granules India's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 1.28.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Granules India's Debt-to-EBITDA or its related term are showing as below:

NSE:GRANULES' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.97   Med: 1.76   Max: 3.32
Current: 1.53

During the past 13 years, the highest Debt-to-EBITDA Ratio of Granules India was 3.32. The lowest was 0.97. And the median was 1.76.

NSE:GRANULES's Debt-to-EBITDA is ranked better than
51.82% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.625 vs NSE:GRANULES: 1.53

Granules India Debt-to-EBITDA Historical Data

The historical data trend for Granules India's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Granules India Debt-to-EBITDA Chart

Granules India Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.46 0.97 1.52 1.23 1.53

Granules India Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.23 - 1.61 - 1.28

Competitive Comparison of Granules India's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Granules India's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Granules India's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Granules India's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Granules India's Debt-to-EBITDA falls into.



Granules India Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Granules India's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(11628.95 + 1521.69) / 8603.82
=1.53

Granules India's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(11628.95 + 1521.69) / 10303
=1.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Granules India  (NSE:GRANULES) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Granules India Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Granules India's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Granules India (NSE:GRANULES) Business Description

Traded in Other Exchanges
Address
3rd Block, My Home Hub, 2nd Floor, Madhapur, Hyderabad, TG, IND, 500 081
Granules India Ltd is an India-based pharmaceutical company. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates and finished dosages. Its business is organized into three areas; the Core business which comprises core molecules such as Paracetamol, Ibuprofen, Metformin, Guaifenesin, and Methocarbamol; the Emerging business that focuses on manufacturing APIs and the US Generics. It has one segment Pharmaceutical products including ingredients and intermediaries. Its primary geographic markets are North America, Latin America, Europe, India, and Rest of World.

Granules India (NSE:GRANULES) Headlines

No Headlines